[
    [
        {
            "time": "2018-01-02",
            "original_text": "复星医药：第八届董事会第二次会议(临时会议)决议公告",
            "features": {
                "keywords": [
                    "复星医药",
                    "董事会",
                    "决议公告"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：第八届董事会第二次会议(临时会议)决议公告",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-03-15",
            "original_text": "复星医药旗下复宏汉霖赴港IPO，三年亏10亿元，尚无产品销售收入亏损",
            "features": {
                "keywords": [
                    "复星医药",
                    "复宏汉霖",
                    "IPO",
                    "亏损"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药旗下复宏汉霖赴港IPO，三年亏10亿元，尚无产品销售收入亏损",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-07-05",
            "original_text": "格隆汇港股聚焦(7.05)︱百威亚太全球拟发行16.26亿股用于还债 融创上半年销售额超2100亿元",
            "features": {
                "keywords": [
                    "百威亚太",
                    "融创",
                    "发行股份",
                    "还债",
                    "销售额"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "消费品",
                    "房地产"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(7.05)︱百威亚太全球拟发行16.26亿股用于还债 融创上半年销售额超2100亿元",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-10",
            "original_text": "复星医药(600196.SH)：复宏汉霖向联交所呈交经更新的上市申请(A1表格)",
            "features": {
                "keywords": [
                    "复星医药",
                    "复宏汉霖",
                    "上市申请"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：复宏汉霖向联交所呈交经更新的上市申请(A1表格)",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-05-20",
            "original_text": "复星医药(02196)附属以5.796亿元竞得成都力思特75.9%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "成都力思特",
                    "股权收购"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196)附属以5.796亿元竞得成都力思特75.9%股权",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-06-10",
            "original_text": "复星医药(600196.SH)与重药控股订立销售采购协议",
            "features": {
                "keywords": [
                    "复星医药",
                    "重药控股",
                    "销售采购协议"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)与重药控股订立销售采购协议",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-07-15",
            "original_text": "复星医药(02196.HK)：奥鸿药业拟以5.79亿元收购成都力思特股份75.9085%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "奥鸿药业",
                    "成都力思特",
                    "股权收购"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)：奥鸿药业拟以5.79亿元收购成都力思特股份75.9085%股权",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-08-10",
            "original_text": "复星国际(00656-HK)：复宏汉霖已向联交所呈交经更新上市申请",
            "features": {
                "keywords": [
                    "复星国际",
                    "复宏汉霖",
                    "上市申请"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星国际(00656-HK)：复宏汉霖已向联交所呈交经更新上市申请",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-07-01",
            "original_text": "【华泰医药代雯团队】《第一批国家重点监控合理用药药品目录》点评：靴子落地",
            "features": {
                "keywords": [
                    "华泰医药",
                    "合理用药",
                    "药品目录",
                    "政策"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【华泰医药代雯团队】《第一批国家重点监控合理用药药品目录》点评：靴子落地",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-07-05",
            "original_text": "华泰证券：靴子落地 第一批监控用药目录出台",
            "features": {
                "keywords": [
                    "华泰证券",
                    "监控用药",
                    "目录出台",
                    "政策"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华泰证券：靴子落地 第一批监控用药目录出台",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-09-10",
            "original_text": "复星医药总裁兼CEO吴以芳：加速创新，提升产品力和品牌力",
            "features": {
                "keywords": [
                    "复星医药",
                    "吴以芳",
                    "创新",
                    "产品力",
                    "品牌力"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药总裁兼CEO吴以芳：加速创新，提升产品力和品牌力",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]